Dallas-Fort Worth Leads Texas in Healthcare Companies on Inc. 5000 List

Eighteen healthcare companies in the Dallas-Fort Worth Metropolitan Area made Inc. magazine’s annual 5,000 list, which attempts to chronicle the fastest growing private companies in the nation. That’s more healthcare companies than any other metropolitan area in Texas, and shows the variety that exist here: Home health, tech, pharmaceutical, provider networks, staffing centers, and services companies. Full Story

Texas Shares in $125 Million Settlement Over Drug Maker’s Monopoly Scheme

Texas is one of 48 states to share in a $125 million settlement with pharmaceutical company Cephalon related to a drug monopoly of the narcolepsy drug it produces, Provigil. The states alleged that Pennsylvania-based Cephalon caused generic versions of the drug to be delayed for several years. Full Story

Nominations Are Open for D CEO’s 2016 Excellence in Healthcare Awards

This year’s edition will be a little different (you’ll see!), but we’re still eager to receive nominations in these 11 categories. We’re looking for stories of remarkable volunteers all the way up to the hardworking executives, from the big hospital systems to the scrappy independents. Wellness programs, community outreach, medical real estate—by the time you’re done reading the feature, we hope we’ve provided a comprehensive view of the healthcare industry in Dallas-Fort Worth and those that are pioneering new care models, cost-saving techniques, and population health strategies. Full Story

Commission Wants More Generic Drugs For Medicare Part D Recipients

A report by an independent advisory commission is pressuring Congress to encourage prescribing generic drugs under its prescription drug program and boost payer incentives for negotiating cheaper prices with the manufacturers. NPR reports on the Medicare Payment Advisory Commission report, which pointed to a 60 percent spike in Medicare Part D spending from 2007 to 2014 as being primarily caused by high drug costs. The commission wants Congress to slash copayments for generics, establish an out-of-pocket spending cap that wouldn’t be affected by manufacturer discounts, and mandate that payers put forth 80 percent of drug costs after patients hit their… Full Story